Follicular Thyroid Cancer Drug Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : December 2019 Pages : 147 Category: Pharma & Healthcare Report Code : HC127603
Follicular Thyroid Cancer Drug Market by Type (Dabrafenib Mesylate, Sunitinib Malate, Cabozantinib S-Malate, Everolimus) Application (Rubber Retarder, Rubber Accelerator) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Follicular Thyroid Cancer Drug Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Thyroid cancer is a type of malignant cancer which is generated from the par follicular and follicular thyroid cells. The treatments that are available for thyroid cancer are the surgical removal of the radioactive ablation, thyroid gland and thyroid stimulating hormone (TSH) suppression therapy. In the progressive stage and metastasis cases, chemotherapy is also useful.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Exelixis, Inc.
- AstraZeneca PLC
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis AG
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Follicular Thyroid Cancer Drug Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Dabrafenib Mesylate
o Sunitinib Malate
o Cabozantinib S-Malate
o Everolimus
· Follicular Thyroid Cancer Drug Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Rubber Retarder
o Rubber Accelerator
· Follicular Thyroid Cancer Drug Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Exelixis, Inc.
o AstraZeneca PLC
o GlaxoSmithKline plc
o Pfizer Inc.
o Novartis AG
· Follicular Thyroid Cancer Drug Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Follicular Thyroid Cancer Drug Market , By Country
o U.S. Follicular Thyroid Cancer Drug Market
o Canada Follicular Thyroid Cancer Drug Market
o Mexico Follicular Thyroid Cancer Drug Market
o Europe
§ Europe Follicular Thyroid Cancer Drug Market , By Country
· Germany Follicular Thyroid Cancer Drug Market
o UK Follicular Thyroid Cancer Drug Market
o France Follicular Thyroid Cancer Drug Market
o Russia Follicular Thyroid Cancer Drug Market
o Italy Follicular Thyroid Cancer Drug Market
o Rest of Europe Follicular Thyroid Cancer Drug Market
o Asia-Pacific
§ Asia-Pacific Follicular Thyroid Cancer Drug Market , By Country
o China Follicular Thyroid Cancer Drug Market
o Japan Follicular Thyroid Cancer Drug Market
o South Korea Follicular Thyroid Cancer Drug Market
o India Follicular Thyroid Cancer Drug Market
o Southeast Asia Follicular Thyroid Cancer Drug Market
o Rest of Asia-Pacific Follicular Thyroid Cancer Drug Market
o South America
§ South America Follicular Thyroid Cancer Drug Market
o Brazil Follicular Thyroid Cancer Drug Market
o Argentina Follicular Thyroid Cancer Drug Market
o Columbia Follicular Thyroid Cancer Drug Market
o Rest of South America Follicular Thyroid Cancer Drug Market
o Middle East and Africa
§ Middle East and Africa Follicular Thyroid Cancer Drug Market
o Saudi Arabia Follicular Thyroid Cancer Drug Market
o UAE Follicular Thyroid Cancer Drug Market
o Egypt Follicular Thyroid Cancer Drug Market
o Nigeria Follicular Thyroid Cancer Drug Market
o South Africa Follicular Thyroid Cancer Drug Market
o Rest of MEA Follicular Thyroid Cancer Drug Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Follicular Thyroid Cancer Drug Market, By Type
5.1. Introduction
5.2. Global Follicular Thyroid Cancer Drug Revenue and Market Share by Type (2017-2027)
5.2.1. Global Follicular Thyroid Cancer Drug Revenue and Revenue Share by Type (2017-2027)
5.3. Dabrafenib Mesylate
5.3.1. Global Dabrafenib Mesylate Revenue and Growth Rate (2017-2027)
5.4. Sunitinib Malate
5.4.1. Global Sunitinib Malate Revenue and Growth Rate (2017-2027)
5.5. Cabozantinib S-Malate
5.5.1. Global Cabozantinib S-Malate Revenue and Growth Rate (2017-2027)
5.6. Everolimus
5.6.1. Global Everolimus Revenue and Growth Rate (2017-2027)
6. Follicular Thyroid Cancer Drug Market, By Application
6.1. Introduction
6.2. Global Follicular Thyroid Cancer Drug Revenue and Market Share by Application (2017-2027)
6.2.1. Global Follicular Thyroid Cancer Drug Revenue and Revenue Share by Application (2017-2027)
6.3. Rubber Retarder
6.3.1. Global Rubber Retarder Revenue and Growth Rate (2017-2027)
6.4. Rubber Accelerator
6.4.1. Global Rubber Accelerator Revenue and Growth Rate (2017-2027)
7. Follicular Thyroid Cancer Drug Market, By Region
7.1. Introduction
7.2. Global Follicular Thyroid Cancer Drug Revenue and Market Share by Regions
7.2.1. Global Follicular Thyroid Cancer Drug Revenue by Regions (2017-2027)
7.3. North America Follicular Thyroid Cancer Drug by Countries
7.3.1. North America Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2027)
7.3.2. North America Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Follicular Thyroid Cancer Drug by Countries
7.4.1. Europe Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2027)
7.4.2. Europe Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Follicular Thyroid Cancer Drug by Countries
7.5.1. Asia-Pacific Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Follicular Thyroid Cancer Drug by Countries
7.6.1. South America Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2027)
7.6.2. South America Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Follicular Thyroid Cancer Drug by Countries
7.7.1. Middle East and Africa Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Exelixis, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. AstraZeneca PLC
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. GlaxoSmithKline plc
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Pfizer Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Novartis AG
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
9. Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.1. Global Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Follicular Thyroid Cancer Drug Market Forecast by Regions (2017-2027)
9.2.1. North America Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.1.1. United States Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.1.2. Canada Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.1.3. Mexico Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2. Europe Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.1. Germany Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.2. France Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.3. UK Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.4. Russia Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.5. Italy Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3. Asia-Pacific Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.1. China Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.2. Japan Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.3. Korea Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.4. India Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.4. South America Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.4.1. Brazil Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.4.2. Argentina Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.4.3. Columbia Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.4.4. Rest of South America Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5. Middle East and Africa Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.3. Egypt Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.4. Nigeria Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.5. South Africa Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.6. Turkey Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Follicular Thyroid Cancer Drug Market Forecast (2017-2027)
9.3. Follicular Thyroid Cancer Drug Market Forecast by Type (2017-2027)
9.3.1. Follicular Thyroid Cancer Drug Forecast by Type (2017-2027)
9.3.2. Follicular Thyroid Cancer Drug Market Share Forecast by Type (2017-2027)
9.4. Follicular Thyroid Cancer Drug Market Forecast by Application (2017-2027)
9.4.1. Follicular Thyroid Cancer Drug Forecast by Application (2017-2027)
9.4.2. Follicular Thyroid Cancer Drug Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Follicular Thyroid Cancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Follicular Thyroid Cancer Drug Revenue and Revenue Share by Type (2017-2018)
Figure Global Dabrafenib Mesylate Revenue and Growth Rate (2017-2018)
Figure Global Sunitinib Malate Revenue and Growth Rate (2017-2018)
Figure Global Cabozantinib S-Malate Revenue and Growth Rate (2017-2018)
Figure Global Everolimus Revenue and Growth Rate (2017-2018)
Table Global Follicular Thyroid Cancer Drug Revenue and Revenue Share by Application (2017-2018)
Figure Global Rubber Retarder Revenue and Growth Rate (2017-2018)
Figure Global Rubber Accelerator Revenue and Growth Rate (2017-2018)
Table Global Follicular Thyroid Cancer Drug Revenue by Regions (2017-2018)
Figure North America Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure North America Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2018)
Figure North America Follicular Thyroid Cancer Drug by Countries (2017-2018)
Figure North America Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure United States Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure United States Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Canada Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Mexico Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Europe Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2018)
Figure Europe Follicular Thyroid Cancer Drug by Countries (2017-2018)
Figure Europe Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Germany Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Germany Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure France Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure UK Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Russia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Italy Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Rest of Europe Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Asia-Pacific Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Follicular Thyroid Cancer Drug by Countries (2017-2018)
Figure Asia-Pacific Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure China Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure China Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Japan Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Korea Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure India Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Southeast Asia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure South America Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2018)
Figure South America Follicular Thyroid Cancer Drug by Countries (2017-2018)
Figure South America Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Brazil Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Argentina Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Columbia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Rest of South America Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Middle East and Africa Follicular Thyroid Cancer Drug Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Follicular Thyroid Cancer Drug by Countries (2017-2018)
Figure Middle East and Africa Follicular Thyroid Cancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Saudi Arabia Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure United Arab Emirates Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Egypt Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Nigeria Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure South Africa Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Turkey Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Follicular Thyroid Cancer Drug Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Table Exelixis, Inc. Follicular Thyroid Cancer Drug Financial Overview
Table AstraZeneca PLC Follicular Thyroid Cancer Drug Financial Overview
Table GlaxoSmithKline plc Follicular Thyroid Cancer Drug Financial Overview
Table Pfizer Inc. Follicular Thyroid Cancer Drug Financial Overview
Table Novartis AG Follicular Thyroid Cancer Drug Financial Overview
Figure Global Follicular Thyroid Cancer Drug Revenue (Millions USD) and Growth Rate (2018-2025)
Table Follicular Thyroid Cancer Drug Market Forecast by Regions (2018-2025)
Figure North America Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure United States Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Canada Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Mexico Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Europe Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Germany Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure France Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure UK Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Russia Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Italy Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Rest of Europe Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Asia-Pacific Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure China Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Japan Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Korea Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure India Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Southeast Asia Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure South America Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Brazil Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Argentina Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Columbia Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Rest of South America Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Middle East and Africa Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Saudi Arabia Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure United Arab Emirates Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Egypt Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Nigeria Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure South Africa Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Turkey Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Follicular Thyroid Cancer Drug Market Forecast (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Forecast by Type (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Market Share Forecast by Type (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Forecast by Type (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Forecast by Application (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Market Share Forecast by Application (2018-2025)
Figure Global Follicular Thyroid Cancer Drug Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|